Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked with the SMCC linker and the cytotoxic microtubule inhibitor DM1. The ADC's toxic and linker components are SMCC-DM1. Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used for cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked with the SMCC linker and the cytotoxic microtubule inhibitor DM1. The ADC's toxic and linker components are SMCC-DM1. Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used for cancer research. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Target | NaPi2b |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.